Genmab AS (GMAB)vsRegeneron Pharmaceuticals Inc (REGN)
GMAB
Genmab AS
$26.11
+1.16%
HEALTHCARE · Cap: $15.94B
REGN
Regeneron Pharmaceuticals Inc
$749.47
+1.05%
HEALTHCARE · Cap: $78.41B
Smart Verdict
WallStSmart Research — data-driven comparison
Regeneron Pharmaceuticals Inc generates 286% more annual revenue ($14.34B vs $3.72B). REGN leads profitability with a 31.4% profit margin vs 25.9%. REGN appears more attractively valued with a PEG of 1.56. REGN earns a higher WallStSmart Score of 58/100 (C).
GMAB
Buy54
out of 100
Grade: C-
REGN
Buy58
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-187.1%
Fair Value
$10.47
Current Price
$26.11
$15.64 premium
Margin of Safety
-165.8%
Fair Value
$281.93
Current Price
$749.47
$467.54 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Keeps 26 of every $100 in revenue as profit
Attractively priced relative to earnings
Strong operational efficiency at 23.0%
Keeps 31 of every $100 in revenue as profit
Safe zone — low bankruptcy risk
Large-cap with strong market position
Attractively priced relative to earnings
Reasonable price relative to book value
Strong operational efficiency at 23.1%
Areas to Watch
Expensive relative to growth rate
3.0% revenue growth
Weak financial health signals
Earnings declined 94.4%
Expensive relative to growth rate
2.5% revenue growth
Weak financial health signals
Earnings declined 2.6%
Comparative Analysis Report
WallStSmart ResearchBull Case : GMAB
The strongest argument for GMAB centers on Price/Book, Debt/Equity, Altman Z-Score. Profitability is solid with margins at 25.9% and operating margin at 23.0%.
Bull Case : REGN
The strongest argument for REGN centers on Profit Margin, Altman Z-Score, Market Cap. Profitability is solid with margins at 31.4% and operating margin at 23.1%.
Bear Case : GMAB
The primary concerns for GMAB are PEG Ratio, Revenue Growth, Piotroski F-Score.
Bear Case : REGN
The primary concerns for REGN are PEG Ratio, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
GMAB carries more volatility with a beta of 0.75 — expect wider price swings.
GMAB is growing revenue faster at 3.0% — sustainability is the question.
GMAB generates stronger free cash flow (1.8B), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
REGN scores higher overall (58/100 vs 54/100), backed by strong 31.4% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Genmab AS
HEALTHCARE · BIOTECHNOLOGY · USA
Genmab A / S develops antibody therapies for the treatment of cancer and other diseases mainly in Denmark. The company is headquartered in Copenhagen, Denmark.
Visit Website →Regeneron Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?